CRDF
Cardiff Oncology, Inc.
Healthcare · Biotechnology · NCM
$1.50
Data: 2026-05-13
✗ ETHICAL FAIL

MOAT
HIGH
Data Confidence: 100.0%
Key Metrics

How this company measures up on the fundamentals that matter

Market Cap
$117M
Total market value of the company
Trailing P/E
0.00
Forward P/E
-2.44
Based on estimated future earnings — lower means cheaper
Rev Growth
+60.9%
Year-over-year revenue change
Profit Margin
0.0%
How much profit the company keeps from each dollar of revenue
ROE
-71.5%
Return on equity — how efficiently it uses shareholder money
Analyst Target
$7.69
+413% from current price — median analyst estimate
Recommendation
STRONG_BUY
Consensus view from 8 analysts covering this stock
About Cardiff Oncology, Inc.

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for the treatment of patients confirmed metastatic and unresectable colorectal cancer in patients with a KRAS or NRAS mutation; and TROV-054, a Phase 1b/2 single-arm clinical trial in KRAS-mutated metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.

https://www.cardiffoncology.com

Country: United States Employees: 30 Industry: Biotechnology
Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity
PASS
Core business does not involve prohibited activities
Debt Ratio
0.7% PASS
Debt must be below 33% of total assets
Cash Ratio
50.0% FAIL
Interest-bearing cash below 33% of assets
Receivables
0.0% PASS
Receivables below 49% of assets
Revenue Purity
0.0% PASS
Non-compliant revenue below 5% — any excess requires purification
Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime
ACCUMULATION
Smart money appears to be building positions quietly
Sharpe Ratio
0.190
Positive but modest risk-adjusted returns
Kelly Fraction
-0.0373
No positive edge detected — the data suggests staying out
Calmar Ratio
-0.317
Drawdown risk outweighs the returns — higher risk profile
Annual Return
-22.9%
Historical annualised return based on price data
Max Drawdown
-72.3%
Largest peak-to-trough decline — the worst it has been
HMM State
BULL
Statistical model sees bullish momentum
Days in State
61
How long the current regime has persisted — longer means more stable
Market Data

Trading characteristics and market positioning

Beta
1.36
Moves slightly more than the broader market
52W High
$4.56
67% below the year high
52W Low
$1.48
1% above the year low
Avg Volume
693,672
Average daily shares traded — higher means easier to buy and sell
Short Ratio
25.5
Days it would take all short sellers to cover — higher means more crowded
Short % Float
27.5%
Very high short interest — potential squeeze candidate
Div Yield
0.0%
Annual dividend as a percentage of the share price
EPS (TTM)
$-0.69
Earnings per share over the last 12 months
Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity
0.02
Conservative use of debt — low financial risk
Current Ratio
3.67
Strong balance sheet — comfortably covers short-term obligations
Quick Ratio
3.59
Like current ratio but excludes inventory — stricter test
Gross Margin
N/A
Revenue left after cost of goods — higher means pricing power
Operating Margin
-3,221.0%
Profit from core operations before interest and tax
Free Cash Flow
$-19,617,000
Negative — the business is spending more than it generates
Revenue (TTM)
$593,000
Total revenue over the last 12 months
Net Income
$-45,876,000
Loss-making — spending exceeds revenue after all costs
Analyst Coverage
Analysts
8
Target High
$12.00
Target Median
$7.69
Target Low
$2.00
Recent Insider Activity

SEC Form 4 filings — what company insiders are buying and selling

Date Insider Title Type Shares Value
2020-01-02 ERLANDER MARK Officer 261 —
2020-01-01 ERLANDER MARK Officer 1,250 —
2019-10-01 ERLANDER MARK Officer 1,250 —
2019-07-01 ERLANDER MARK Officer 1,250 —
2019-04-01 ERLANDER MARK Officer 1,250 —
2019-01-02 ERLANDER MARK Officer 1,563 —
2019-01-01 ERLANDER MARK Officer 7,500 —
Source: SEC Form 4 filings via public data. View all insider activity at
Insider Intelligence
Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-13

Discover More
Alpha Insights Market Intelligence Titan Watch Ethical Screener Insider Intelligence Track Record Ethical Finance Zakat Calculator Iran Oil Tracker Foundry (292 articles) Indicators Join Free →

Get our weekly market brief free.